RCHOP14

RCHOP14 is a dose-dense chemotherapy regimen used for certain B-cell non-Hodgkin lymphomas, administered on a 14-day cycle. The regimen combines rituximab with the CHOP components: cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone. The 14-day cycle length distinguishes it from the standard R-CHOP schedule, which is typically given every 21 days.

In practice, rituximab is given on day 1 of each cycle, followed by the CHOP chemotherapy within the same cycle. The overall cycle duration is 14 days, and many treatment plans include hematopoietic growth-factor support to maintain dose density and reduce the risk of prolonged neutropenia. Dosing is tailored to body surface area and local protocol, with supportive care such as antiemetics and, when appropriate, antimicrobial prophylaxis.

RCHOP14 has been studied primarily in aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma and mantle cell lymphoma, with the aim of improving response rates and progression-free survival through a dose-dense approach. Some trials have reported higher complete response rates or longer remissions in certain patient groups, but the regimen is associated with increased toxicity, notably neutropenia and infection, and is not universally adopted. Patient selection typically considers age, comorbidities, and tolerance for intensified treatment.

Common toxicities include neutropenia, febrile neutropenia, mucositis, nausea, vomiting, neuropathy, and cardiotoxicity from doxorubicin. Growth-factor support and careful cardiac monitoring are routinely used. RCHOP14 is one option within the broader family of R-CHOP schedules, with regimen choice influenced by individual patient factors and institutional experience.